Hepatitis Monthly
Official Journal of Research Center for Gastroenterology and Liver Diseases
Scopus by Title (Ref)
1. Efficacy and safety of anti-Hepatitis C virus regimens containing daclatasvir: a systematic review and meta-analysis from Egypt
- Abdel-Gawad M. , et al.
2. High Efficiency and Safety of Hepatitis C Treatment Among People Who Inject Drugs in Vietnam
- Laureillard D. , et al.
3. Highly sensitive and selective β-Ni(OH)2@CNTs modified electrode for detection of Anti-Hepatitis C
- Adolf M.L. , et al.
4. Cost–Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong
- Yuen M.F. , et al.
6. Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy
- Ruggeri M. , et al.
7. Acute changes in cardiac function by direct acting antiviral therapy for hepatitis C−infected patients with thalassemia
- Khosravi A. , et al.
9. Effectiveness and tolerability of direct-acting antivirals for chronic hepatitis C patients in a Southern state of Brazil
- Ferreira V. , et al.
10. Comment on 'Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: The ANRS HC32 QUATTRO study'
- Alavian S. , et al.
11. Reply to: “Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries”
- Zeuzem S. , et al.
12. Update on recommendations for the clinical management of hepatitis C in Iran 2017
- Alavian S.M. , et al.
13. HIV/HCV coinfection and the risk of cardiovascular disease: A meta-analysis
- Osibogun O. , et al.
15. Budget impact and cost-effectiveness analyses of direct-acting antivirals for chronic hepatitis C virus infection in Hong Kong
- Li X. , et al.
16. Association of vitamin D binding protein polymorphisms with response to therapy in Egyptian chronic hepatitis C patients
- Kamel A.M. , et al.
17. Efficacy and safety of ledipasvir/ sofosbuvir for the treatment of chronic hepatitis c in persons with sickle cell disease
- Moon J. , et al.
18. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment
- Poordad F. , et al.
19. Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy
- Kozuka R. , et al.
20. A cross-sectional study of hepatitis C among people living with HIV in Cambodia: Prevalence, risk factors, and potential for targeted screening
- Weggheleire A.D. , et al.
21. The safety and effectiveness of ledipasvir−sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection
- Balistreri W.F. , et al.
22. Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens
- Puenpatom A. , et al.